STOCK TITAN

Fortrea Holdings - FTRE STOCK NEWS

Welcome to our dedicated page for Fortrea Holdings news (Ticker: FTRE), a resource for investors and traders seeking the latest updates and insights on Fortrea Holdings stock.

Overview

Fortrea Holdings (FTRE) is a global contract research organization (CRO) that delivers comprehensive clinical development solutions across Phase I through IV clinical trials. As a pure-play CRO, Fortrea is dedicated to managing clinical trial processes, clinical pharmacology, and consulting services with a strong emphasis on scientific rigor and technological innovation. From its inception as an independent company spun off from Labcorp's clinical development business, Fortrea has distinguished itself through its extensive experience, deep industry insights, and a worldwide network spanning over 90 countries.

Core Business and Services

Fortrea’s core business revolves around offering robust clinical trial management solutions. The company provides:

  • Comprehensive Trial Management: From early-phase safety studies to expansive post-approval studies, Fortrea supports every step of the clinical research continuum.
  • Clinical Pharmacology and Consulting: Leveraging decades of cumulative experience, Fortrea delivers expert advice and technical services that ensure studies meet regulatory requirements and scientific standards.
  • Patient Access Solutions: Focused on optimizing patient recruitment and retention, the company designs and implements effective strategies that ensure diverse patient participation in clinical trials.

These services are executed with an unwavering commitment to quality and compliance, ensuring that clinical research adheres to rigorous safety and regulatory guidelines.

Global Reach and Industry Expertise

Fortrea's operations are underpinned by a strong global presence, with teams operating in numerous countries and a broad network of investigator sites. This expansive network not only supports clinical trials across multiple therapeutic areas but also enables the company to maintain close relationships with a diverse range of biopharmaceutical, biotechnology, and medical device clients. The company’s operations are characterized by:

  • Decades of Industry Experience: With over 30 years of cumulative expertise, Fortrea’s understanding of more than 20 therapeutic areas speaks to its domain mastery.
  • Rigorous Scientific and Operational Excellence: The organization has institutionalized processes that stress scientific rigor, transparency, and agile operational practices.
  • Robust Regulatory Compliance: As clinical trials must meet stringent regulatory demands, Fortrea emphasizes quality controls and risk-based monitoring to ensure adherence to global standards.

Innovation and Technological Integration

Fortrea is strategically advancing its service offerings through the adoption of innovative technologies. Recognizing that speed, precision, and patient safety are critical in clinical development, the company has invested in integrating artificial intelligence and machine learning solutions that enhance operational efficiency. Specific technology initiatives include:

  • AI-Enabled Systems: These systems support trial simulations, predictive analytics, and pattern recognition, optimizing trial design and execution.
  • Digital Transformation: Modernizing IT systems to provide a consumer-grade, omni-channel experience enhances data accuracy and speeds up decision-making processes for clinical trials.
  • Operational Automation: Utilizing advanced analytics and automated data collection methods, Fortrea aims to minimize administrative burdens, allowing clinical teams to focus on the critical human elements of trial oversight and patient care.

Positioning Within the Competitive Landscape

Within the competitive environment of the CRO industry, Fortrea distinguishes itself not through speculative forward-looking promises but through its demonstrable expertise and deep operational competence. By concentrating on core clinical development areas and divesting non-core segments, the company has streamlined its focus towards delivering superior clinical trial management services. This strategic refinement allows Fortrea to better serve both emerging and established biopharmaceutical companies by driving efficiency and improved outcomes in clinical research.

Commitment to Excellence

Fortrea’s commitment to operational excellence is evident in its methodical approach to clinical trial management, underscored by its integration of cutting-edge technology and a robust global network. Its strategic practices are designed to support a transparent, methodical, and scientifically backed clinical trial process that adds significant value to its stakeholders—from trial sponsors to the patients who benefit from advanced therapies.

News
Rhea-AI Summary
Fortrea (Nasdaq: FTRE) convened the inaugural meeting of its Site Advisory Board, aiming to improve the clinical trial experience for sites, patients, and sponsors. The Board includes leaders from 440 sites across 25 therapeutic areas and nine countries, focusing on driving changes in technology, operational planning, and community engagement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.16%
Tags
management
-
Rhea-AI Summary
Fortrea (Nasdaq: FTRE) reported third-quarter 2023 financial results, including revenues of $776.4 million, a GAAP net loss of $13.1 million, and an adjusted EBITDA of $70.5 million. The company's book-to-bill ratio was 1.24x, and it provided a financial guidance for 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.61%
Tags
-
Rhea-AI Summary
Fortrea, a leading global contract research organization (CRO), has completed a multi-year effort to expand its clinical pharmacology solutions and capacity. The expansion includes a state-of-the-art facility in Leeds, U.K., as well as new or renovated space in Dallas, Texas; Daytona, Florida; and Madison, Wisconsin. The company aims to accurately assess early pipeline candidates and speed up their development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.18%
Tags
Rhea-AI Summary
Fortrea appoints John Doyle as President of Consulting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.47%
Tags
management
-
Rhea-AI Summary
Fortrea to release Q3 2023 financial results and host conference call
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.27%
Tags
-
Rhea-AI Summary
Fortrea's Global CISO, Jim Cameli, named to HotTopics' Global CISO 100 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.14%
Tags
none
Rhea-AI Summary
Fortrea to participate in fireside chat at Morgan Stanley healthcare conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.25%
Tags
conferences
-
Rhea-AI Summary
Fortrea to participate in fireside chat at Baird Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.25%
Tags
conferences
-
Rhea-AI Summary
Fortrea (Nasdaq: FTRE) reported Q2 2023 revenues of $793.0 million, GAAP net income of $28.3 million, and adjusted EBITDA of $72.5 million. The company also provided a full-year financial outlook.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.21%
Tags
Rhea-AI Summary
Fortrea (Nasdaq: FTRE) announces release of second quarter 2023 financial results and conference call. Investors can register online for the earnings call and access the webcast link. Replay will be available on the company's Investor Relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.11%
Tags

FAQ

What is the current stock price of Fortrea Holdings (FTRE)?

The current stock price of Fortrea Holdings (FTRE) is $5.5 as of April 22, 2025.

What is the market cap of Fortrea Holdings (FTRE)?

The market cap of Fortrea Holdings (FTRE) is approximately 438.4M.

What core services does Fortrea Holdings provide?

Fortrea offers comprehensive clinical trial management across Phases I-IV, clinical pharmacology, and consulting services. The company also provides patient access solutions to enhance trial participation and retention.

How does Fortrea generate revenue?

Fortrea generates revenue by partnering with biopharmaceutical, biotechnology, medical device, and diagnostic companies on clinical trials and related services. Its revenue streams are primarily derived from service fees for trial management and consulting expertise.

How does Fortrea differentiate itself in the CRO industry?

Fortrea differentiates itself through its global scale, decades of industry expertise, and an integrated approach that combines scientific rigor with advanced technology. Its focus on becoming a pure-play CRO enhances its specialization in clinical trial management.

What is the significance of Fortrea's technological integration?

The company integrates AI and machine learning to optimize processes such as trial simulations and predictive analytics. This technology-driven approach reduces administrative burdens and improves patient safety throughout the clinical trial process.

What industries does Fortrea primarily serve?

Fortrea serves emerging and large-scale biopharmaceutical companies, as well as firms in biotechnology, medical devices, and diagnostics. Its services are designed to meet the diverse needs of the life sciences industry.

How extensive is Fortrea's global presence?

Fortrea operates in over 90 countries, supported by a vast global network of investigator sites and clinical research professionals. This global reach reinforces its ability to manage trials across a multitude of therapeutic areas.

How does Fortrea ensure regulatory and quality compliance?

Fortrea adheres to rigorous quality control measures and risk-based monitoring to meet global regulatory standards. Its systematic approach focuses on maintaining high scientific and operational standards throughout every phase of clinical trials.
Fortrea Holdings

Nasdaq:FTRE

FTRE Rankings

FTRE Stock Data

438.37M
89.89M
0.31%
105.63%
7.64%
Biotechnology
Services-medical Laboratories
Link
United States
DURHAM